Brief: Context Therapeutics Says Co Amended Collaboration, Licensing Agreement With Integral Molecular

Context Therapeutics

06/03/2024 12:41

March 6 (Reuters) - Context Therapeutics Inc  CNTX.O :
    * CONTEXT THERAPEUTICS - ON FEB 29, AMENDED COLLABORATION,
LICENSING AGREEMENT WITH INTEGRAL MOLECULAR, INC.
    * CONTEXT THERAPEUTICS - AGREEMENT FOR DEVELOPMENT OF A
CLDN6
BISPECIFIC MONOCLONAL ANTIBODY FOR CANCER THERAPY
    * CONTEXT THERAPEUTICS - DETERMINED THAT CERTAIN OF THE
LICENSED
RIGHTS MAY INCORPORATE INTELLECTUAL PROPERTY RIGHTS CURRENTLY
HELD BY A THIRD PARTY
    * CONTEXT THERAPEUTICS - AS PER AMENDMENT, AGGREGATE
DEVELOPMENT
AND REGULATORY MILESTONE PAYMENTS WILL BE REDUCED FROM $55
MILLION TO $15 MILLION
    * CONTEXT THERAPEUTICS - AS PER AMENDMENT, AGGREGATE SALES
MILESTONE PAYMENTS WILL BE REDUCED FROM $130 MILLION TO $12.5
MILLION

Source text for Eikon:  ID:n0001842952-24-000005 
Further company coverage:  CNTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))